Analyst Ratings For Merrimack Pharmaceuticals (NASDAQ:MACK)
Today, Robert W. Baird reiterated its Hold rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a price target of $12.00.
Some recent analyst ratings include
- 3/15/2018-Robert W. Baird Reiterated Rating of Hold.
- 5/19/2017-Cowen Reiterated Rating of Market Perform.
- 11/10/2016-JPMorgan Chase & Co. Reiterated Rating of Hold.
- 11/10/2016-BTIG Research Reiterated Rating of Neutral.
- 5/20/2016-Mizuho Reiterated Rating of Buy.
Recent Insider Trading Activity For Merrimack Pharmaceuticals (NASDAQ:MACK)
Merrimack Pharmaceuticals (NASDAQ:MACK) has insider ownership of 8.53% and institutional ownership of 54.07%.
- On 9/15/2017 Ulrik B Nielsen, Director, sold 7,896 with an average share price of $14.23 per share and the total transaction amounting to $112,360.08.
- On 9/14/2017 Ulrik B Nielsen, Director, sold 100 with an average share price of $14.20 per share and the total transaction amounting to $1,420.00.
- On 9/13/2017 Ulrik B Nielsen, Director, sold 21,556 with an average share price of $14.40 per share and the total transaction amounting to $310,406.40.
- On 9/11/2017 Ulrik B Nielsen, Director, sold 14,756 with an average share price of $14.46 per share and the total transaction amounting to $213,371.76.
- On 5/12/2017 Daryl C Drummond, Insider, sold 4,097 with an average share price of $3.72 per share and the total transaction amounting to $15,240.84.
- On 7/25/2016 Birgit M Schoeberl, Insider, sold 50,000 with an average share price of $5.50 per share and the total transaction amounting to $275,000.00.
- On 3/17/2016 Michael E Porter, Director, bought 5,000 with an average share price of $7.20 per share and the total transaction amounting to $36,000.00.
Recent Trading Activity for Merrimack Pharmaceuticals (NASDAQ:MACK)
Shares of Merrimack Pharmaceuticals closed the previous trading session at with 10.329999923706055 shares trading hands.